Evidence map›Paper›PMID 41552384›Full record

ArticleMolecular therapy. Nucleic acids2026

Poly(A) variants supporting robust transmission stability in bacteria and high protein expression in animals for mRNA

Hua Chen, Wei Qin, Hui Bao, Xuwei Chen, Xu Ye, Yi Wang, Liang Liu, Yanguang Zhang, Ying Sun, Tingting Zhang and 3 more

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hua ChenRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Wei QinRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Hui BaoRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Xuwei ChenRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Xu YeRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Yi WangRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Liang LiuRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Yanguang ZhangRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Ying SunRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Tingting ZhangRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Yijie DongRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.
Shan CenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Weiguo ZhangRinuaGene Biotechnology Co., Ltd., Suzhou, Jiangsu, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly(A) tail is crucial in regulating mRNA stability and protein translation. Thus, it is an essential element of mRNAs transcribed

Indexed as

in vitro transcriptionmRNA therapeuticsmRNA vaccineMT: Oligonucleotides: Therapies and Applicationspoly(A)protein expressiontransmission stability

Identifiers

PMID41552384
PMCPMC12811438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.